Determination of Busulfan in Plasma from Pediatric Patients by UPLC-MS/MS

CHAI Huixia, ZHANG Haifeng, SHAO Duanfang, QUAN Li, CUI Xiaodai, LIU Rong

PDF(2462 KB)
主办：上海医药工业研究院
　　　中国药学会
　　　中国化学制药工业协会
ISSN 1001-8255   CN 31-1243/R   ZYGZEA
Adv Search
Chinese Journal of Pharmaceuticals
PDF(2462 KB)
Chinese Journal of Pharmaceuticals ›› 2022, Vol. 53 ›› Issue (06) : 876-882. DOI: 10.16522/j.cnki.cjph.2022.06.016
Paper

Determination of Busulfan in Plasma from Pediatric Patients by UPLC-MS/MS

Author information +
History +

Abstract

An ultra-high performance liquid chromatography-tandem mass spectrometry(UPLC-MS/MS) method was established for the determination of busulfan(1) in plasma from pediatric patients. The ACQITY UPLC? HSS T3 column(2.1 mm×50 mm, 1.8 μm) was used, and the multiple reaction monitoring mode was adopted with the electrospray ion source for positive ion segmental scanning analysis. The results showed that it was linear for 1 in the range of 20 - 3 000 ng/ml, and the quantification limit of the method was 5 ng/ml. The intra- and inter-day precisions were below 5％. The average extraction recoveries were 90％ - 110％, and the residual effect was 0.01％. The concentration of 1 decreased by 22％ after storage at room temperature for 24 h, indicating that the plasma sample was unstable under this condition. While under the other storage conditions(4, –20 and–80 ℃), the concentrations of 1 were basically unchanged within one week. The established method required a small amount of plasma sample, and even 1 μl of plasma could be used for detection. This method was fast, accurate and reliable, which provided a reference for pediatric therapy and pharmacokinetic studies of 1.

Key words

busulfan / UPLC-MS/MS / therapeutic drug monitoring / pediatric patient

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations
CHAI Huixia, ZHANG Haifeng, SHAO Duanfang, QUAN Li, CUI Xiaodai, LIU Rong. Determination of Busulfan in Plasma from Pediatric Patients by UPLC-MS/MS. Chinese Journal of Pharmaceuticals. 2022, 53(06): 876-882 https://doi.org/10.16522/j.cnki.cjph.2022.06.016

References

[1] STROUSE C, ZHANG Y, ZHANG M J, et al．Risk score for the development of veno-occlusive disease after allogeneic
hematopoietic cell transplant [J]．Biol Blood Marrow Transplant, 2018, 24(10): 2072-2080．
[2] EDUARDO F P, BEZINELLI L M, GOBBI M, et al．Retrospective study of the digestive tract mucositis derived from myeloablative and non-myeloablative/reducedintensity conditionings with busulfan in hematopoietic cell transplantation patient [J]．Support Care Cancer, 2019,27(3): 839-848．
[3] THEBAULT S, LEE H, BOSE G, et al．Neurotoxicity after hematopoietic stem cell transplant in multiple sclerosis [J]．
Ann Clin Transl Neurol, 2020, 7(5): 767-775．
[4] BARTELINK I H, LALMOHAMED A, VAN REIJ E M L,et al．Association of busulfan exposure with survival and toxicity after haemopoietic cell transplantation in children and young adults: a multicentre, retrospective cohort analysis[J]．Lancet Haematol, 2016, 3(11): e526-e536．
[5] SORA F, GRAZIA C D, CHIUSOLO P, et al．Allogeneic hemopoietic stem cell transplants in patients with acute myeloid leukemia(AML) prepared with busulfan and fludarabine(BUFLU) or thiotepa, busulfan, and fludarabine(TBF): a retrospective study [J]．Biol Blood Marrow Transplant, 2020, 26(4): 698-703．
[6] 黄菁菁, 陈 冰, 杨婉花．谷胱甘肽转移酶基因多态性对白消安体内代谢的影响[J]．中国临床药理学杂志, 2012,28(11): 869-871．
[7] 冯新颖, 吴云娇, 李佳朋, 等．白消安个体化给药的群体药代动力学研究现状[J]．中国临床药理学杂志, 2018,34(24): 2884-2888．
[8] 郑 萍, 刘世霆, 李春富, 等．白消安在儿童和成人造血干细胞移植预处理患者体内的药动学研究[J]．中国药学杂志, 2013, 48(13): 1088-1093．
[9] ZEKI ? C, EYLEM C C, RE?BER T, et al．Integration of GC-MS and LC-MS for untargeted metabolomics profiling[J]．J Pharm Biomed Anal, 2020, 190: 113509．
[10] DAVID V, MOLDOVEANU S C, GALAON T．Derivatization procedures and their analytical performances for HPLC determination in bioanalysis [J]．Biomed Chromatogr, 2021, 35(1): e5008．
[11] BAIG M A, SWAMY K B, BAKSH A D, et al．Evaluation of role of HPLC(merits & pitfalls), in the diagnosis of various hemoglobinopathies & thalassemic syndromes [J]．Indian J Pathol Microbiol, 2021, 64(3): 518-523．
[12] MATAR K M, ALSHEMMARI S H, REFAAT S, et al．UPLC-Tandem mass spectrometry for quantification of busulfan in human plasma: application to therapeutic drug monitoring [J]．Sci Rep, 2020, 10(1): 8913．
[13] IALONGO C, MOZZI A F, BERNARDINI S．An LCMS assay with isocratic separation and on-line solid phase extraction to improve the routine therapeutic drug monitoring of busulfan in plasma [J]．J Med Biochem, 2017, 36(2):113-121．
[14] MOON S Y, LIM M K, HONG S, et al．Quantification of human plasma-busulfan concentration by liquid chromatography-tandem mass spectrometry [J]．Ann Lab Med, 2014, 34(1): 7-14．
[15] XIAO Y, LI X H, FU X W．A rapid and simple LC-MS/MS method for personalized busulfan dosing in pediatric patients
undergoing hematopoietic stem cell transplantation(HSCT)[J]．Clin Chim Acta, 2018, 479: 190-195．
[16] ZHANG H F, QUAN L, PEI P, et al．Simultaneous determination of vitamin A, 25-hydroxyl vitamin D α-tocopherol in small biological fluids by liquid chromatography-tandem mass spectrometry [J]．J Chromatogr B Analyt Technol Biomed Life Sci, 2018, 1079:1-8．
[17] Center for Drug Evaluation and Research．Guidance for industry applications covered by section 505(b) [EB/OL]．[2021-12-23]．https://webarchive．library．unt．edu/eot2008/20080920150033/http://www．fda．gov/cder/guidance/2853dft．htm．
[18] DANSO D, JANNETTO P J, ENGER R, et al．Highthroughputvalidated method for the quantitation of busulfan in plasma using ultrafast SPE-MS/MS [J]．Ther Drug Monit, 2015, 37(3): 319-324．
[19] LEE E J, PARK N, LEE S H, et al．A simple and accurate liquid chromatography-tandem mass spectrometry method for therapeutic drug monitoring of busulfan in plasma [J]．Ann Clin Lab Sci, 2019, 49(2): 212-217．
[20] WILEY M B, PEREZ P A, ARGUETA D A, et al．UPLCMS/MS method for analysis of endocannabinoid and related lipid metabolism in mouse mucosal tissue [J]．Front Physiol, 2021, 12: 699712．
[21] YE Z J, WU L J, ZHANG X Y, et al．Quantification of sorafenib, lenvatinib, and apatinib in human plasma for therapeutic drug monitoring by UPLC-MS/MS [J]．J Pharm Biomed Anal, 2021, 202: 114161．
[22] SUN D L, QIU N N, ZHOU S, et al．Development of sensitive and reliable UPLC-MS/MS methods for food analysis of emerging mycotoxins in China total diet study[J]．Toxins, 2019, 11(3): 166．
[23] 黄菁菁, 陈 冰, 杨婉花．HPLC法测定人血浆中白消安的浓度[J]．中国药师, 2013, 16(3): 395-397．
[24] PARISE R A, COVEY J M, HOLLINGSHEAD M G, et al．Development and validation of an LC-MS/MS generic assay platform for small molecule drug bioanalysis [J]．J Pharm Biomed Anal, 2021, 203: 114185．
[25] PUNT A M, LANGENHORST J B, EGAS A C, et al．Simultaneous quantification of busulfan, clofarabine and F-ARA-A using isotope labelled standards and standard addition in plasma by LC-MS/MS for exposure monitoring in hematopoietic cell transplantation conditioning [J]．J Chromatogr B Analyt Technol Biomed Life Sci, 2017, 1055:81-85．
[26] 谢何琳, 庄波阳, 吴雪梅, 等．HPLC-MS-MS法测定白消安的血药浓度[J]．海峡药学, 2014, 26(11): 243-246．
[27] JINJIE Y, SUN N, ZHANG S, et al．A rapid HPLC-MS/MS method for determining busulfan in hemolytic samples from children with hematopoietic stem cell transplantation [J]．Biomed Chromatogr, 2020, 34(9): e4898．
[28] 朱丽娜, 董 吉, 缪丽燕．人血浆中白消安血药浓度的测定[J]．抗感染药学, 2016, 13(6): 1216-1219．
[29] 王 磊, 孙文丽, 刘红星．HPLC-MS/MS法测定白血病患者血浆白消安浓度[J]．医学检验与临床, 2018, 29(3):36-39．
[30] SATO M, KAKO S, MATSUMOTO K, et al．Pharmacokinetics study of once-daily intravenous busulfan in conditioning regimens for hematopoietic stem cell transplantation [J]．Int J Hematol, 2015, 101(5): 497-504．
PDF(2462 KB)

220

Accesses

0

Citation

Detail
Sections
Recommended

/

〈 〉